Accreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Commercial Support
This activity is supported by educational grants from AstraZeneca, Clovis Oncology, Inc., and Sanofi Genzyme.
Cancer Summaries and Commentaries™: Update from Barcelona: Advances in the Treatment of Genitourinary Cancers
Release Date: November 27, 2019
Expiration Date: November 27, 2020
Media: Internet - based
Activity Overview
This online activity is designed to update physicians on data presented at the 2019 Annual Meeting, held in September in Barcelona, Spain. Cancer Summaries and Commentaries™: Update from Barcelona: Advances in the Treatment of Genitourinary Cancers online continuing medical education (CME) activity facilitates critical assessment and clinical integration of new evidence, when appropriate. The activity reviews 8 abstracts with some of the most compelling and clinically relevant genitourinary (GU) cancer presentations from the meeting. For each abstract, a short summary of key clinical data is accompanied by expert perspectives that provide insight into how clinicians can apply these findings to their clinical practice to improve patient care.
Benefits of Participating
- Hear from the experts about recent clinical trials in the field of GU malignancies and their impact on clinical practice decision making
- Identify opportunities to implement emerging treatments for the management of urothelial, renal and prostate cancer
- Explore the role of biomarkers in the treatment and management of GU malignancies
Acknowledgement of Commercial Support
This activity is supported by educational grants from AstraZeneca, Clovis Oncology, Inc., and Sanofi Genzyme.
Instructions for This Activity and Receiving Credit
|
Target Audience
This educational activity is directed toward medical oncologists and fellows who treat patients with genitourinary cancers. Urologists, surgical oncologists, radiation oncologists, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of genitourinary cancers will be invited to participate.
Learning Objectives
Upon successful completion of this educational activity, you should be better prepared to:
- Outline methods that allow for optimized characterization of tumor biology among patients with genitourinary malignancies.
- Explain the study design, rationale and results of recent clinical trials evaluating novel strategies for the treatment of genitourinary malignancies.
- Consider recent evidence in the context of evolving treatment paradigms in the management of genitourinary Malignancies.
Faculty, Staff, and Planners’ Disclosures
Faculty
Associate Professor; Co-Director, Kidney Cancer Program
Department of Medical Oncology & Experimental Therapeutics
City of Hope Comprehensive Cancer Center
SWOG RCC Translational Medicine Chair
Associate Editor, ASCO Cancer.Net
Duarte, CA
Disclosures: Consultant: Genentech, AVEO Oncology, Eisai Inc., Roche, Pfizer, Novartis, Exelixis, Ipsen, Bristol-Myers Squibb, Astellas Pharma.
Professor, Medicine and Urology
University of Washington
Member, Fred Hutchinson Cancer Research Center
Seattle, WA
Disclosures: Grant Research Support: Aptevo Therapeutics, Aragon Pharmaceuticals, Astellas Pharma, AstraZeneca, Bayer, Dendreon, Genentech, Hoffman LaRoche, Medivation, Sanofi, Pfizer; Consultant: Aptevo Therapeutics, Asana BioSciences, Astellas Pharma, Bayer, Blue Earth Diagnostics, Churchill Pharmaceuticals, Clovis Oncology, Dendreon, Endocyte, Ferring Pharmaceuticals, Medivation, Orion Corporation, Pfizer.
The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.
Disclosure Policy and Resolution of Conflicts of Interest (COI)
As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a COI.
Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic or treatment options for a specific patient’s medical condition.
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or the company that provided commercial support.
Login or Register to Start Activity
Please use the form below to Register or Log In to begin Activity.